Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.43%
#2 Audiera Audiera +20.35%
#3 Ocean Protocol Ocean Protocol +17.12%
#4 Geodnet Geodnet +14.56%
#5 Arowana Arowana +7.05%
#6 Cysic Cysic +7.00%
#7 Rollbit Coin Rollbit Coin +6.33%
#8 The Bitcoin Bull The Bitcoin Bull +6.07%
#9 Ontology Gas Ontology Gas +5.24%
#10 Perle Perle +4.88%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Настройки
Язык
Pусский
Валюта
USD
Тема
NuCana plc NuCana plc

NuCana plc

NCNA
Ранг среди акций #32775
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Цена акции
$1.51
Последняя синхронизация: 2026-08-17
Рыночная капитализация
$9.14M
Изменение (1 день)
-5.35%
Изменение (1 год)
-61.11%
Страна
GB
Торговля NuCana plc (NCNA)

Категория

Healthcare
История дивидендов NuCana plc (NCNA)
NuCana plc (тикер: NCNA) выплатила в общей сложности 0 дивидендов.
Общая сумма всех дивидендов (с учетом дроблений акций): 0.00
Дивидендная доходность (TTM): 0
Дивидендные выплаты по NuCana plc (NCNA) с 2026 по 2026
Годовые дивидендные выплаты
Год Дивиденды (с учетом дробления акций) Изменить
Недостаточно данных для указанных дат.
Список всех дивидендных выплат
Год Дивиденд Изменить
Недостаточно данных для указанных дат.
Дивиденды аналогичных компаний или конкурентов
Компания Количество дивидендных выплат Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00%
KR